Objectives To investigate the mechanism of integron mediated resistance and multidrug-resistance in P.aeruginosa.Methods The variable region of integron was amplified by integron PCR.Restriction fragment length polymorphism(RFLP)and DNA sequencing were used to investigate the resistance genes in the variable region of integron.Results Of the 98 strains 35(35.7%)were the variable region positive,and size of the amplicons ranged from 1.0 kb to 4.0 kb.A total of 6 different cassette arrays were detected,including genes coding resistance to aminoglycosides,?-lactam compounds and sulfanilamides.Of the 5 cassette arrays 3 were novel,including aadA6-orfD,aadB-blaP1 and aadB-aac6-Ⅱ-blaCARB-8,and the Genbank numbers were DQ 091179,DQ 141316 and DQ 288251 respectively.Conclusions Integron mediates the resistance and multidrug resistance in P.aeruginosa.The majority of the genes located in integrons are those coding resistance to aminoglycosides.Three strains of class I integron with novel cassette arrays are reported.

In order to go deeply into the researches on the theory of hemodynamics for interventional treatment of lung cancer, we have designed a simulating experimental system. Using the experimental system, we can simulate the operation process and test the effect of drug infusion under a variety of physiological parameters. The parameters that admit of adjustment are: cardiac output, blood pressure of aorta, waveform of pressure, pulse period, blood flow in bronchial artery and different types of catheter, injecting velocity, injecting technique, etc. In addition, the entrance position and blood vessel diameter of small embranchment artery can be changed. In this paper are presented the application of our pH-testing method to natural infusion region and the determined representational shape and size.
Antineoplastic Agents ; administration & dosage ; Bronchial Arteries ; physiology ; Cardiac Output ; Catheterization ; Computer Simulation ; Heart Rate ; Hemodynamics ; Humans ; Infusions, Intra-Arterial ; Lung Neoplasms ; drug therapy ; physiopathology ; Models, Cardiovascular

Objective: To investigate the feasibility and indication of free grafting of split big toe nail bed for defects of fingernail bed. Methods: From September 2008 to September 2011, 13 cases (4 females and 9 males) with fingernail bed defects(aged 17-38, average, 32) were treated with split big toe nail bed. The split big toe nail was harvested according to the defects size without bone exposure at donor site. Results: Three grafted nail beds were necrotic completely and reconstructed with flaps. The 2 grafted nail bed was partial loss and healed after dressing. All the other grafted nail bed survived completely with primarily healing both in donor sites and recipient sites. The patients were followed up for 6-30 months(average, 14 months). The therapeutic effect was graded as excellent in 8 cases, good in 2 cases and poor in 14 cases(good rate, 76.9%). The nail matrix was excellent in 8 cases, good in 1 case and poor in 1 case(good rate, 90%). The toe nails in donor sites grew well. Conclusions The single fingernail defect with intact nail matrix can be reconstructed by split toe nail bed graft with good cosmetic and functional effect. There is no malfunction at donor site. The indication should be selected.

Objective: To observe and study clinical efficacy of restruction of finger pulp using tibial flap. Methods: From January 2009 to October 2013, we reconstructed the 20 finger pulps with free tibial flap of the second toe. Results: 20 flaps survived completely and were followed up for 6 months to 2 years, with an average of 1 year. There were no obvious scars in the reconstructive finger pulps. And the reconstructed finger pulps all had good appearance, texture, a fingerprint point discrimination at 6-8 mm, and finger function recovered well. Conclusions The shape of finger pulp after reconstuction with the free tibial flap of the second toe has the similar appearance to the normal finger pulp and a good sensory function, which is one of the best ways to reconstruct the finger pulp defects.

Objective To investigate the expression of pepsin in vocal cord polyps and vocal cord cancer,and to compare the difference of pepsin expression.Methods From May 2020 to December 2021,27 patients with vocal cord polyp,27 patients with vocal cord cancer and 23 healthy volunteers were selected.RSI and RFS scoring scales were used for scoring,pepsin detection kit was used for saliva pepsin detection,and immunohistochemical methods were used to detect the expression of pepsin in vocal cord tissues of patients with vocal cord polyps and vocal cord cancer.Results The RSI score,RFS score and pepsin test kit results of vocal cord polyp group and vocal cord canc-er group were higher than those of non-vocal cord disease group,and the differences of the three indexes were statis-tically significant(P＜0.05).RSI score,pepsin detection kit results and pepsin immunohistochemistry results of vocal cord polyp group showed no significant difference compared with vocal cord cancer group(P＞0.05).The RFS score of vocal cord polyp group was significantly different from that of vocal cord cancer group(P＜0.05).Conclusion Pepsin may be an important pathogenic factor of vocal cord polyp and vocal cord cancer,and play an im-portant role in the occurrence of these two diseases.The difference of pepsin expression in vocal cord polyp and vo-cal cord cancer suggests that pepsin may have different pathogenesis.

BACKGROUND: Vancomycin treatment failure against vancomycin-susceptible gram-positive cocci is not rare in the intensive care unit (ICU). One of the reasons for this is the substandard drug trough concentration. We aimed to examine the hypothesis that the target serum concentration could be reached earlier with a loading dose of vancomycin. METHODS: This retrospective cohort study was conducted at our ICU between June 2018 and June 2020 and involved patients who were suspected of having, or confirmed to have, gram-positive cocci infection and treated with vancomycin. One group of the patients was administered a loading dose of vancomycin (loading group) and compared with the group that did not receive a loading dose (control group). The baseline characteristics, vancomycin serum concentrations, and clinical outcomes were collected and analyzed. RESULTS: Fifty-five patients were finally included, of which 29 received a loading dose of vancomycin. The serum concentration of vancomycin before the second dose was significantly higher for the loading group than for the control group (10.3 ± 6.1 mg/L vs. 5.7 ± 4.4 mg/L, P = 0.002). The results for both groups were similar before the fifth dose (12.4 ± 7.3 mg/L vs. 10.3 ± 6.3 mg/L in the loading and the control groups, respectively; P = 0.251). The 28-day mortality was lower for the loading group than for the control group (6.7% vs. 34.6% in the loading and control groups, respectively; P = 0.026). No significant differences were observed in serum creatinine (Cr) concentrations of the two groups. CONCLUSION: With the loading dose of vancomycin, the target serum concentration of vancomycin may be reached earlier without increasing the risk of acute kidney injury. TRIAL REGISTRATION https://www.chictr.org.cn; ChiCTR2000035369.
Anti-Bacterial Agents/therapeutic use* ; Creatinine ; Humans ; Intensive Care Units ; Retrospective Studies ; Vancomycin

Compared with conventional radiotherapy fields, small field has unique dosimetry characteristics such as high dose gradient, charged particle imbalance, and dose effect caused by source occlusion. These characteristics increase the difficulty of dose measurement and thus the uncertainty of clinical dose measurement, far exceeding the requirement of < 5% measurement error in ICRU 24 report. In recent years, with the development of new radiotherapy technologies, the minimum radiotherapy field can reach the millimeter level, and the single irradiation dose of hypofractionated radiotherapy can exceed 6 Gy. The larger dose gradient at the edge of radiotherapy field requires higher accuracy of dose measurement, and accurate small field dosimetry technologies have gradually become a research hotspot in the field of precision radiotherapy. In order to ensure the high accuracy of measurement, this paper reviews the research on small field dosimetry worldwide, and summarizes the key points of small field dosimetry. In this paper, the characteristics of small field dosimetry are introduced, and the current small field dosimetry technologies and optimization methods are summarized, including the optimization of detector selection and detector sensitive volume. The field output correction factor technologies are analyzed. In view of the difficulty in small field dosimetry, this paper provides suggestions on dosimetry based on clinical needs and the characteristics of medical linear accelerators. Our suggestions provide a scientific reference for small field dosimetry in clinical practice in radiotherapy institutions, and facilitate the development of radiotherapy dose verification.

BACKGROUND: Immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the standard treatment for patients with non-oncogenic advanced non-small cell lung cancer (NSCLC). While lung cancer is most prevalent in elderly patients, these patients are rarely included in pivotal clinical trial studies. We aimed to describe the efficacy and safety of immunotherapy for elderly patients in the "real-world". METHODS: The data of older NSCLC patients and younger patients who received immunotherapy between July 2018 to October 2021 were retrospectively analyzed and the objective response rate (ORR) and progression-free survival (PFS) in different age groups (less than 60 years old was defined as the young group, 60 years-74 years old was the young old group, 75 years old and above was the old old group) were compared. And the impact of different clinical characteristics on treatment response and prognosis were analyzed in each age subgroup. RESULTS: A total of 21 young patients, 70 young old patients and 15 old old patients were included in this study, with ORR of 33.3%, 52.8% and 53.3%, respectively, without statistically significant difference (P=0.284). The median PFS was 9.1 mon, 7.6 mon and 10.9 mon, respectively, without statistically significant difference (P=0.654). Further analysis of the predictors of immunotherapy in each subgroup revealed that patients in the young old group and young group who received immunotherapy in the first line had a longer PFS. The difference of the incidence of adverse events was not statistically significant among the three groups (P>0.05). CONCLUSIONS The efficacy and safety of immunotherapy in elderly patients were similar to those in younger patients, and PFS was superior in the first-line immunotherapy. Further prospective studies are still needed to explore predictors of immunotherapy in elderly NSCLC patients.
Aged ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Humans ; Immunotherapy/adverse effects* ; Lung Neoplasms/drug therapy* ; Middle Aged ; Prognosis ; Retrospective Studies